BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24899787)

  • 1. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments.
    Li S; Jin T; Zhang HL; Yu H; Meng F; Concha Quezada H; Zhu J
    Mediators Inflamm; 2014; 2014():740947. PubMed ID: 24899787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome.
    Li S; Yu M; Li H; Zhang H; Jiang Y
    Mediators Inflamm; 2012; 2012():260473. PubMed ID: 23091305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barré syndrome.
    Liang SL; Wang WZ; Huang S; Wang XK; Zhang S; Wu Y
    Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):1039-46. PubMed ID: 22738814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.
    Han RK; Cheng YF; Zhou SS; Guo H; He RD; Chi LJ; Zhang LM
    J Clin Immunol; 2014 Jan; 34(1):94-103. PubMed ID: 24217817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Th22 cells, as well as Th17 cells, are elevated in patients with renal cell carcinoma.
    Peng Z; Hu Y; Ren J; Yu N; Li Z; Xu Z
    Int J Med Sci; 2021; 18(1):99-108. PubMed ID: 33390778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis.
    Wang X; Zheng XY; Ma C; Wang XK; Wu J; Adem A; Zhu J; Zhang HL
    Scand J Immunol; 2014 Sep; 80(3):180-90. PubMed ID: 24910360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high frequency of circulating th22 and th17 cells in patients with new onset graves' disease.
    Peng D; Xu B; Wang Y; Guo H; Jiang Y
    PLoS One; 2013; 8(7):e68446. PubMed ID: 23874630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.
    Maddur MS; Rabin M; Hegde P; Bolgert F; Guy M; Vallat JM; Magy L; Bayry J; Kaveri SV
    Immunol Res; 2014 Dec; 60(2-3):320-9. PubMed ID: 25391612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia.
    Chen P; Wang M; Li D; Jia Y; He N; Li W; Ma D; Ji C
    J Immunol Res; 2015; 2015():416123. PubMed ID: 26000313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
    Zhang HL; Zheng XY; Zhu J
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):443-53. PubMed ID: 23791985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated frequencies of circulating Th22 cell in addition to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome.
    Zhang L; Wang T; Wang XQ; Du RZ; Zhang KN; Liu XG; Ma DX; Yu S; Su GH; Li ZH; Guan YQ; Du NL
    PLoS One; 2013; 8(12):e71466. PubMed ID: 24312440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of altered Th17 pathway signatures in the cerebrospinal fluid of patients with Guillain Barré Syndrome.
    Debnath M; Nagappa M; Dutta D; Talukdar PM; Subbanna M; Shivakumar V; Wahatule R; Sinha S; Bindu PS; Periyavan S; Umamaheswara Rao GS; Kumar MA; Taly AB
    J Clin Neurosci; 2020 May; 75():176-180. PubMed ID: 32217048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis.
    Zhang L; Li JM; Liu XG; Ma DX; Hu NW; Li YG; Li W; Hu Y; Yu S; Qu X; Yang MX; Feng AL; Wang GH
    J Clin Immunol; 2011 Aug; 31(4):606-14. PubMed ID: 21556937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus.
    Yang XY; Wang HY; Zhao XY; Wang LJ; Lv QH; Wang QQ
    J Clin Immunol; 2013 May; 33(4):767-74. PubMed ID: 23435610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.
    Yu S; Liu C; Zhang L; Shan B; Tian T; Hu Y; Shao L; Sun Y; Ji C; Ma D
    Int J Mol Sci; 2014 Jan; 15(2):1927-45. PubMed ID: 24473142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer.
    Zhang W; Tian X; Mumtahana F; Jiao J; Zhang T; Croce KD; Ma D; Kong B; Cui B
    BMC Cancer; 2015 Oct; 15():717. PubMed ID: 26474968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.
    Brem MD; Jacobs BC; van Rijs W; Fokkink WJR; Tio-Gillen AP; Walgaard C; van Doorn PA; IJspeert H; van der Burg M; Huizinga R
    Ann Clin Transl Neurol; 2019 Jan; 6(1):129-143. PubMed ID: 30656191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Th17, Th22, and Th1 cells are increased in psoriasis.
    Kagami S; Rizzo HL; Lee JJ; Koguchi Y; Blauvelt A
    J Invest Dermatol; 2010 May; 130(5):1373-83. PubMed ID: 20032993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased percentages of regulatory T cells are necessary to activate Th1-Th17-Th22 responses during acute rejection of the peripheral nerve xenotransplantation in mice.
    Chai H; Yang L; Gao L; Guo Y; Li H; Fan X; Wu B; Xue S; Cai Y; Jiang X; Qin B; Zhang S; Ke Y
    Transplantation; 2014 Oct; 98(7):729-37. PubMed ID: 25093516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Th22, Th17 and CD4
    Doulabi H; Rastin M; Shabahangh H; Maddah G; Abdollahi A; Nosratabadi R; Esmaeili SA; Mahmoudi M
    Biomed Pharmacother; 2018 Jul; 103():1101-1106. PubMed ID: 29710675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.